FDA approves Perrigo's miconazole
This article was originally published in The Tan Sheet
FDA approves Perrigo's abbreviated new drug application for the private-label version of Monistat-1 Combination Pack. Perrigo's OTC Miconazole Nitrate Vaginal Cream and Suppository will ship immediately, the Allegan, Mich.-based private label firm says June 3. Johnson & Johnson/McNeil's Monistat generates about $90 million in annual sales, Perrigo pointed out. Perrigo also said patent litigation by J&J was dismissed, and the approval includes 180 days of generic marketing exclusivity. Analysts with Collins Stewart say the launch of Perrigo's store-brand Monistat product is positive and "gives us greater confidence in [Perrigo's] manufacturing capabilities.
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.